The VEGF‐A mRNA has been shown to improve cardiac function after myocardial infarction in preclinical models.[55, 56] Recently, naked VEGF‐A mRNA in a citrate saline solution (without LNPs as RNA carriers) was applied in clinical trials in patients with type 2 diabetes,[57] and patients undergoing coronary artery bypass grafting (CABG).[58, 59, 60] However, currently there is no known effective and safe carrier to deliver therapeutic VEGF‐A mRNA to the heart which could potentially stimulate VEGF‐A‐dependent blood vessel formation. This evidence concerns the gene VEGFA and myocardial infarction.